Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient [letter]

Lt, Brunozzi; Meniconi, Luigi; Chiocchi, P.; Liberati, Rita; Zuanetti, Giulio; Latini, Roberto

doi:10.1111/j.1365-2125.1988.tb03413.x

Cited by 22 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings on transplacental distribution are consistent with those of Brunozzi et al (1988) showing that both propafenone and 5-OH-propafenone are transferred to the foetus without harmful effects during the last trimester of pregnancy.…”

supporting

confidence: 90%

Transfer of propafenone and 5‐OH‐propafenone to foetal plasma and maternal milk [letter]

Libardoni

Piovan

Busato

et al. 1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

supporting

confidence: 90%

Transfer of propafenone and 5‐OH‐propafenone to foetal plasma and maternal milk [letter]

Libardoni

Piovan

Busato

et al. 1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…23) Propafenone was reported to be safe in the treatment of ventricular arrhythmia during pregnancy. 24) Combination therapy (Class IC drugs plus beta-blocking drugs, or amiodarone plus beta-blocking drugs) frequently is effective in preventing recurrent VT. Unfortunately, amiodarone therapy during pregnancy (category D) may cause fetal/neonatal hypothyroidism and, less frequently, goiter.…”

Section: Discussionmentioning

confidence: 99%

Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy

et al. 2014

View full text Add to dashboard Cite

SummaryArrhythmogenic right ventricular cardiomyopathy (ARVC) is predominantly a genetically determined heart muscle disorder that is characterized by fibro-fatty replacement of the right ventricular (RV) myocardium.1) The clinical spectrum of ARVC may represent from asymptomatic premature ventricular complexes to ventricular tachycardia (VT) and sudden cardiac death (SCD). It is a well-known leading cause of SCD in young adults. 2,3)There is no general consensus on the management of ARVC in pregnancy, and the preferred mode of delivery is uncertain. Herein, we report a case of ARVC diagnosed at 20 weeks of gestation following a sustained VT and treated with an implantable cardiac defibrillator (ICD). We also reviewed the current knowledge and approach to ARVC in pregnancy since the literature on this condition is based on case reports. (Int Heart J 2014; 55: 372-376)

show abstract

“…Treatment of ARVD is based on the prevention of arrhythmia with β-blockers, especially with sotalol, which prevents arrhythmia caused by ARVD in 60% to 70% of patients [ 9 ]. Propafenone is reported to be safe in the treatment of ventricular arrhythmia during pregnancy [ 10 ]. ICD use is recommended for patients who have had a documented episode of sustained VT or cardiac arrest or who have high-risk features for SCA [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Management of a rare case of arrhythmogenic right ventricular dysplasia in pregnancy: a case report

et al. 2011

View full text Add to dashboard Cite

IntroductionArrhythmogenic right ventricular dysplasia is a heritable disease of the heart muscle characterized by fibrofatty degeneration of cardiomyocytes. Patients present with ventricular arrhythmias or congestive heart failure, and sometimes sudden cardiac death occurs. Prenatal diagnosis has become possible with the detection of mutations, but, to the best of our knowledge, no case of prenatal diagnosis has been reported previously. There is little information about the management of arrhythmogenic right ventricular dysplasia in pregnancy, and the preferred mode of delivery is not certain; therefore, we present the case of a patient with arrhythmogenic right ventricular dysplasia and discuss the prenatal diagnosis, patient management and prognosis in pregnancy.Case presentationA 26-year-old Caucasian woman who presented to our hospital with heart palpitations was diagnosed with arrhythmogenic right ventricular dysplasia, and, after three years of follow up with anti-arrhythmic drugs, she wanted to conceive. During pregnancy, she ceased taking her medication. She tolerated pregnancy very well but her cardiac symptoms recurred after her 30th week of pregnancy. She delivered a baby via cesarean section under general anesthesia in her 38th week of pregnancy. She was discharged without any medications and continued lactation for six months.ConclusionPatients with mild to moderate arrhythmogenic right ventricular dysplasia tolerate pregnancy and breastfeeding very well, but patients with end-stage arrhythmogenic right ventricular dysplasia should be discouraged from conception.

show abstract

Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient [letter]

Cited by 22 publications

References 7 publications

Transfer of propafenone and 5‐OH‐propafenone to foetal plasma and maternal milk [letter]

Transfer of propafenone and 5‐OH‐propafenone to foetal plasma and maternal milk [letter]

Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy

Management of a rare case of arrhythmogenic right ventricular dysplasia in pregnancy: a case report

Contact Info

Product

Resources

About